Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 09/12/2024 at 12:05, 2 months 9 days ago

Moderna R&D Day Highlights Progress and Strategic Priorities

COVID-19 Vaccine Financial Outlook Vaccine Approvals Moderna Updates R&D Strategy
PRESS RELEASE

published on 09/12/2024 at 12:00, 2 months 9 days ago

Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna, Inc. announces program updates focusing on ten product approvals through 2027, submission of next-gen COVID vaccine and flu/COVID combo vaccine in 2024, positive Phase 3 results for RSV vaccine, and cost efficiency improvements

Moderna Vaccine Phase 3 Results Product Approvals R&D Expense Reduction
BRIEF

published on 09/09/2024 at 13:05, 2 months 12 days ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

Health Canada Moderna MRNA Vaccines Laval Facility Drug Establishment License
PRESS RELEASE

published on 09/09/2024 at 13:00, 2 months 12 days ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Moderna's Laval facility in Canada attains Drug Establishment License, a key step towards onshore mRNA vaccine production by 2025. This milestone boosts national vaccine supply

Canada Manufacturing Facility Moderna MRNA Vaccines Drug Establishment License
BRIEF

published on 09/05/2024 at 14:05, 2 months 16 days ago

EMA Recommends Authorization of Moderna's Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Authorization COVID-19 Vaccine Moderna EMA SARS-CoV-2 Variant
PRESS RELEASE

published on 09/05/2024 at 14:00, 2 months 16 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 receives positive opinion from CHMP for European Commission authorization decision for 2024-2025 vaccination season

COVID-19 Vaccine European Commission Moderna MRNA Spikevax
BRIEF

published on 09/03/2024 at 14:35, 2 months 18 days ago

Moderna Receives MHRA Authorization for Updated COVID-19 Vaccine Targeting JN.1 Variant

COVID-19 Moderna Vaccine JN.1 Variant MHRA
PRESS RELEASE

published on 09/03/2024 at 14:30, 2 months 18 days ago

Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants

COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF

published on 09/02/2024 at 13:05, 2 months 19 days ago

Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1
PRESS RELEASE

published on 09/02/2024 at 13:00, 2 months 19 days ago

Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna receives approval for updated COVID-19 vaccine formulation targeting SARS-CoV-2 variant JN.1 from Taiwan FDA. Regulatory decisions globally expected soon

COVID-19 Vaccine Moderna Spikevax SARS-CoV-2 Variant Taiwan FDA

Accesswire

Published on 11/21/2024 at 22:05, 1 hour 48 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 2 hours 3 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 3 hours 38 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 43 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 53 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 4 hours 52 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 5 hours 17 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 55 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 6 hours 1 minute ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 6 hours 2 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 16 hours 55 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 4 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 6 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 6 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 16 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE